CompletedPhase 2

A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis

China168 participantsStarted 2025-09-25

Plain-language summary

This study is ongoing to explore the efficacy and safety of different strengths of RSS0393 ointment in adults with atopic dermatitis

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age ≥18 years old and ≤75 years old at screening.
✓. History of atopic dermatitis ≥ 6 months.
✓. BSA is between 3% and 20% (inclusive) and EASI score is ≥ 5 and vIGA-AD is 2 or 3.
✓. The subjects signed informed consent before any study-related procedures began.

✕. Diagnosis of other dermatologic diseases at screening.
✕. Subjects have other skin diseases or conditions that may affect the evaluation of the relevant endpoints of this study.
✕. Subjects with any other persistent active autoimmune disease.
✕. Subjects who have received topical medication for psoriasis within 14 days before baseline, or systemic medication or phototherapy for psoriasis within 28 days before baseline, or biological agents for psoriasis within a specified time before baseline.

Percentage of subjects with vIGA-AD success

Timeframe: Baseline, week 4

NCT IDNCT07158151

SponsorReistone Biopharma Company Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-04-10